Funds
The latest news, updates and opinions on Funds from the expert team here at MoneyWeek
Explore Funds
-

Saba recommends share tender offer if its Edinburgh Worldwide bid is successful
The US-based activist investor looks set to offer Edinburgh Worldwide shareholders a chance to sell their shares at close to NAV if they vote through its proposals for the investment trust’s board
By Dan McEvoy Last updated
-

Last chance to invest in VCTs? Here's what you need to know
Investors have pumped millions more into Venture Capital Trusts (VCTS) so far this tax year, but time is running out to take advantage of tax perks from them.
By Holly Mead Published
-

Profit from MSCI – the backbone of finance
As an index provider, MSCI is a key part of the global financial system. Its shares look cheap
By Rupert Hargreaves Published
-

Should you join the rush for venture-capital trusts?
Opinion Investors hoping to buy into venture-capital trusts before the end of the tax year may need to move quickly, says David Prosser
By David Prosser Published
Opinion -

Barings Emerging Europe trust bounces back from Russia woes
Barings Emerging Europe trust has added the Middle East and Africa to its mandate, delivering a strong recovery, says Max King
By Max King Published
-

The top stocks and funds to buy according to DIY investors
Nvidia dropped out of Interactive Investor’s top ten most-bought stocks in January for the first time in six months as investors veered away from US megacaps
By Dan McEvoy Last updated
-

Are activists coming for your investment trust?
How can you tell if your investment trust might be targeted by activists? We look at the warning signs and how to know when a takeover might not be so bad
By Holly Mead Published
-

Saba Capital is doing wonders for shareholder democracy
Activist hedge fund Saba Capital isn’t popular, but it has ignited a new age of shareholder engagement, says Rupert Hargreaves
By Rupert Hargreaves Published
-

Exciting opportunities in biotech
Biotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
By Max King Published
